Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Oncology

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdp377PMID 19825886PMCID PMC2844945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer

  2009cited by this paper
• Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

  2008cited by this paper
• A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

  2007influential reference
• A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers

  2007cited by this paper
• The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor

  2006cited by this paper
• Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells.

  2006cited by this paper
• Cyclin-dependent kinase pathways as targets for cancer treatment.

  2006cited by this paper
• AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

  2006cited by this paper
• Targeting the cell cycle: a new approach to cancer therapy.

  2005cited by this paper
• Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

  2005cited by this paper
• Bioluminescent imaging of Cdk2 inhibition in vivo

  2004cited by this paper
• A Phase II Clinical and Pharmacodynamic Study of E7070 in Patients with Metastatic, Recurrent, or Refractory Squamous Cell Carcinoma of the Head and Neck

  2004cited by this paper
• Novel approaches in oncology at AstraZeneca

  2003cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000influential reference
• Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.

  2000cited by this paper
• Inactivation of Retinoblastoma Protein in Uveal Melanoma by Phosphorylation of Sites in the COOH-Terminal Region

  2000cited by this paper
• Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.

  1999cited by this paper
• Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes

  1998cited by this paper
• Differential Phosphorylation of the Retinoblastoma Protein by G1/S Cyclin-dependent Kinases*

  1997cited by this paper
• Control of the G1/S transition.

  1997cited by this paper
• Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas

  1997cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• The consensus motif for phosphorylation by cyclin D1‐Cdk4 is different from that for phosphorylation by cyclin A/E‐Cdk2.

  1996influential reference
• The cell cycle kinases.

  1994cited by this paper

• Dual CDK and MEK Inhibition potentiates CD8+ T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer

  2025cites this paper
• LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5

  2025cites this paper
• Recent advances in regulating the cell cycle through inhibiting CDKs for cancer treatment.

  2025cites this paper
• Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss

  2025influential citation
• Cyclin-dependent protein kinases and cell cycle regulation in biology and disease

  2025cites this paper
• PROTACs improve selectivity for targeted proteins

  2025cites this paper
• scPharm: Identifying Pharmacological Subpopulations of Single Cells for Precision Medicine in Cancers

  2024cites this paper
• Inhibitors and PROTACs of CDK2: challenges and opportunities

  2024cites this paper
• Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.

  2024cites this paper
• Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer

  2023cites this paper
• AZD5438 a GSK-3a/b and CDK inhibitor is antiapoptotic modulates mitochondrial activity and protects human neurons from mitochondrial toxins

  2023cites this paper
• A novel prognostic signature contributes to precision treatment in colon adenocarcinoma with KRAS mutation

  2023cites this paper
• Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced AKI

  2023influential citation
• Double‐strand DNA break repair: molecular mechanisms and therapeutic targets

  2023cites this paper
• Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent

  2023cites this paper
• KIF18A and CDK1 as combined therapeutic targets in cervical and endometrial carcinomas: based on bioinformatics analysis and in vitro experiments

  2023cites this paper
• Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future.

  2022cites this paper
• CDK inhibitors from past to present: A new wave of cancer therapy.

  2022cites this paper
• Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

  2022cites this paper
• Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action

  2021cites this paper
• Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.

  2021cites this paper
• Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer

  2021cites this paper
• AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss.

  2021cites this paper
• Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)

  2021cites this paper
• Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment

  2021cites this paper
• Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

  2021cites this paper
• Patient-tailored design of AML cell subpopulation-selective drug combinations

  2020cites this paper
• A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

  2020cites this paper
• Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs

  2020cites this paper
• Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation

  2019cites this paper
• CDK9 as an Appealing Target for Therapeutic Interventions.

  2019cites this paper
• Cyclin‐dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin‐based anticancer therapy: Interaction with carbonyl‐reducing enzymes and ABC transporters

  2019cites this paper
• Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl‐xL silenced cells

  2018cites this paper
• Structural and functional characterisation of cyclin dependent kinase 1 containing complexes

  2018cites this paper
• Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.

  2018cites this paper
• CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner

  2018cites this paper
• Inhibitors of cyclin‐dependent kinases as cancer therapeutics

  2017cites this paper
• Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

  2016cites this paper
• Standing on the shoulders of giants: a retrospective analysis of kinase drug discovery at AstraZeneca.

  2016cites this paper
• Pharmacological cyclin dependent kinase inhibitors: Implications for colorectal cancer.

  2016cites this paper
• Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization

  2016cites this paper
• Targeting metabolic reprogramming associated to cancer cells: search of novel targets and combined therapies in cancer treatment

  2015cites this paper
• Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinoma

  2015cites this paper
• Genome wide expression analysis of radiation-induced DNA damage responses in isogenic HCT116 p53+/+ and HCT116 p53−/− colorectal carcinoma cell lines

  2015cites this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cites this paper
• Amygdalin Blocks Bladder Cancer Cell Growth In Vitro by Diminishing Cyclin A and cdk2

  2014cites this paper
• Dinaciclib for the treatment of breast cancer

  2014cites this paper
• Nonclinical Safety Evaluation of a Transforming Growth Factor β Receptor I Kinase Inhibitor in Fischer 344 Rats and Beagle Dogs

  2014cites this paper
• Targeting cell cycle regulation in cancer therapy.

  2013cites this paper
• Identification de nouvelles structures inhibitrices de kinases : conception synthèse et évaluation biologique

  2013cites this paper
• A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

  2013influential citation
• MammaPrint for Individualized Recurrence Risk Assessment and Treatment Recommendations for Early-Stage Breast Cancer Patients

  2013cites this paper
• BRCA Mutation and PARP Inhibitors

  2013cites this paper
• HPV: Diagnosis, Prevention, and Treatment

  2012cites this paper
• Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

  2012cites this paper
• AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.

  2012cites this paper
• classical Hodgkin lymphoma A molecular risk score based on 4 functional pathways for advanced

  2011cites this paper
• Transcriptional Analysis of an E2F Gene Signature as a Biomarker of Activity of the Cyclin-Dependent Kinase Inhibitor PHA-793887 in Tumor and Skin Biopsies from a Phase I Clinical Study

  2010cites this paper
• Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumors

  2010cites this paper
• Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

  2010cites this paper
• Cyclin-dependent kinase inhibitors: a survey of recent patent literature

  2010cites this paper
• A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma.

  2010cites this paper